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Abstract. Little is known about the function of microRNAs in 
prolactinomas treated with bromocriptine. The aim of the study 
was to explore the microRNAs associated with bromocriptine-
treated prolactinomas. Six prolactinoma samples were selected 
according to whether they received bromocriptine treatment or 
not before microsurgery, and microRNA expression profiles 
of bromocriptine-treated and untreated prolactinomas were 
screened by the miRCURY LNA Array. The differentially 
expressed microRNAs in microarrays were further validated 
by stem-loop real-time PCR and subjected to gene ontology 
analysis and KEGG pathway analysis. In addition, related genes 
of microRNAs were analyzed by qRT-PCR in 15 prolactinoma 
samples. The initial analysis by microarrays generated a list of 
80 upregulated microRNAs and 71 downregulated microRNAs 
in treated prolactinomas compared to untreated prolactinomas. 
miR-206, miR-516b and miR-550 were confirmed to be 
significantly upregulated, while miR-671-5p was confirmed 
to be significantly downregulated in treated prolactinomas by 
qRT-PCR. microRNA-mRNA network analysis integrating 
GO and KEGG pathway annotation displayed some critical 
factors. Platelet-derived growth factor α polypeptide (PDGFA) 
and bone morphogenetic protein 4 (BMP4), were verified to be 
differentially expressed between the two groups. PDGFA was 
significantly upregulated in treated prolactinomas, while BMP4 
was significantly downregulated in treated prolactinomas. Our 
study reveals differential expression of microRNAs in prolac-
tinoma after pharmacotherapy. Specific microRNAs may be 
involved in the inhibition or promotion of prolactinoma tumor 
growth impacted by bromocriptine pharmacotherapy. PDGFA 
and BMP4 may be involved in the pharmacotherapy mecha-
nism of prolactinoma.
Introduction
Dopamine agonist medication is a first-line therapy in the 
treatment of prolactinomas. Bromocriptine can normalize 
the serum prolactin (PRL) level in more than 90% of cases 
and reduce tumor volume in approximately 85% of cases (1). 
Its primary mechanism of action is through the dopamine 2 
(D2) receptor on the cell membrane of prolactin cells, which 
is selectively activated. Thus, the transcription and expres-
sion of the PRL gene and the metabolism of prolactin cells 
are inhibited, leading to decreased synthesis and secretion of 
PRL. In addition, the involution of the endoplasmic reticulum 
and Golgi apparatus, and the suppression of cell prolifera-
tion lead to a reduction in tumor volume (2). The subsequent 
pharmacotherapeutic effect of prolactinoma acts through the 
TGF-β and MAPK signaling pathway to inhibit lactotroph cell 
proliferation and induce apoptosis through D2 receptors (3-5).
microRNAs are approximately 22 nucleotide, non-coding 
RNA generated from endogenous hairpin-shaped transcripts 
which post-transcriptionally regulate the expression of 
protein-coding genes (6) and are thought to be involved in 
several cellular processes regulating differentiation and devel-
opment (7,8). microRNAs may regulate gene expression at the 
post-transcriptional level by direct cleavage of a target mRNA 
using interference machinery (mRNA cleavage) or by inhibi-
tion of protein synthesis, thereby affecting the expression of 
several hundred different target genes (9). microRNAs bind 
to the 3'-untranslated region of target mRNAs, interrupting 
translation or mRNA degradation (6). They are involved in 
microRNA expression profile and differentially-expressed 
genes in prolactinomas following bromocriptine treatment
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several other cellular processes, including differentiation, 
proliferation and death (8). Specific microRNA enrichment 
has been described in the adult mouse pituitary, suggesting that 
microRNAs may regulate pituitary functions (10-12) and devel-
opment (13). Recently, a number of studies have analyzed the 
microRNA expression in pituitary adenomas (14-18). Bottoni 
et al (14) found that miR-15a and miR-16-1 dysregulation may 
affect the expression of genes involved in the development of 
pituitary adenomas. Furthermore, Bottoni et al (15) analyzed 
the entire microRNAome in pituitary adenomas and normal 
pituitary and found that specific microRNAs were identified as 
a predictive signature of pituitary adenoma and its histotype. In 
addition, miR-135a, miR-140-5p, miR-582-3p, miR-582-5p and 
miR-938, which target Smad3 (19), and miR-128a, miR-155 
and miR-516a-3p, which target Wee1 (20), were overexpressed 
in non-functioning pituitary adenomas. Furthermore a group 
set of microRNAs differentially expressed among normal 
pituitaries adenomas and carcinomas has been described 
(21). However, in the current literature, no investigation on 
the alteration of microRNA expression in prolactinomas 
undergoing pharmacological treatment by bromocriptine has 
been performed despite the fact that microRNA expression 
could differentiate treated from non-treated NFPA samples in 
the Bottoni's report (16). In this study, we screen and identi-
fied microRNAs associated with prolactinomas treated with 
bromocriptine, and further analyzed the related genes that 
are also involved in the pharmacotherapeutic mechanism of 
prolactinoma. The present findings may provide a basis to 
comprehend their potential role in the pharmacotherapeutic 
mechanism of prolactinoma.
Patients and methods
Patients. This study was approved by the Ethics Committee 
of Wenzhou Medical College, and written informed consent 
was obtained from all patients. Fifteen postsurgical pitu-
itary adenoma tissue samples were obtained from the First 
Affiliated Hospital of Wenzhou Medical College; data from 6 
of those patients have been previously reported (22) (Table I). 
Tissue samples were collected in accordance with the guide-
lines of the local committee on human research. Patients were 
classified into 2 groups according to whether they received 
bromocriptine treatment or not before microsurgery. Five 
patients of Group A received bromocriptine treatment before 
microsurgery: one patient was not able to tolerate the side 
effects, 3 patients were reluctant to take bromocriptine for 
life, and one patient underwent tumor apoplexy during the 
bromocriptine treatment. In order to eliminate the adverse 
effects of different doses and durations of bromocriptine treat-
ment, bromocriptine, no less than 5 mg per day, was taken for 
at least 8-weeks in this study (Table I). Ten patients (Group B) 
primarily received microsurgery (5 patients with visual 
impairment, 1 with tumor apoplexy, and 4 with an individual 
decision for a primarily surgical treatment). In each patient, 
the diagnosis of a prolactinoma was confirmed by tumor histo-
pathological, immunohistochemical and electron microscopy 
evaluation.
RNA isolation and evaluation. Total RNA was extracted from 
pituitary adenoma tissues using TRIzol reagent (Invitrogen 
Life Technologies, Carlsbad, CA, USA) according to the 
Table I. Patient characteristics of treated and untreated prolactinomas with bromocriptine.
    Initial PRL  BRC daily doses Time with BRC
Case no. Group Gender Age (ng/ml) Tumor size (mg) (months)
  1a A F 35 872.5 Macro+KnospⅠ+SSE 5 2
  2a A M 43 >400 Macro+KnospⅡ+SSE 5.0 15
  3a A F 39 >200 Micro 5 18
  4 A F 27 >200 Macro+KnospⅣ+SSE 7.5 7
  5 A F 35 >200 Macro+KnospⅡ+SSE 7.5 20
  6a B M 45 849 Macro+KnospⅡ+SSE
  7a B M 51 >200 Macro+KnospⅠ
  8a B M 43 >200 Macro+KnospⅡ+SSE
  9 B F 47 287.5 Micro
10 B M 42 1733.6 Macro+KnospⅣ+SSE
11 B M 47 >4000 Macro+KnospⅡ+SSE
12 B M 23 3814 Macro+KnospⅣ+SSE
13 B F 52 >600 Macro+KnospⅣ+SSE
14 B M 38 >200 Macro+KnospⅡ+SSE
15 B M 29 >800 Macro+KnospⅣ
PRL, prolactin; F, female; M, male; BRC, bromocriptine; Macro, macroadenoma; Micro, microadenoma; SSE, supraseller extension. aSix 
patient samples were screened using the miRCURY™ LNA Array. Patient cases 1, 2 and 3 were treated with bromocriptine and cases 6, 7 and 
8 were not treated with bromocriptine before microsurgery.
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manufacturer's instructions with some modifications as previ-
ously described (23). RNAs were incubated at -20˚C for at least 
2 h to enhance precipitation efficiency of low-molecular-weight 
(LMW) RNAs. Following a wash with 80% ethanol, RNA was 
resuspended in DEPC-treated water and stored at -80˚C. The 
concentration and purity of total RNA were qualified by an 
ultraviolet spectrophotometer at 260 and 280 nm.
microRNA microarray. Six high-density expression arrays 
were used (Group A patient cases 1, 2 and 3; Group B patient 
cases 6, 7 and 8) (Table I) to analyze the microRNA expres-
sion. The samples were labeled using the miRCURY™ Hy3™/
Hy5™ Power labeling kit and hybridized on miRCURY LNA 
Array (v.10.0) containing capture probes for 856 microRNAs, 
listed in miRBase (Sanger miRBase Release 10.0) http://
microrna.sanger.ac.uk). A common reference consisting of a 
mix of the products was spotted on the array. Accordingly, 
a ratio can be calculated for every spot, and expression 
levels across different hybridizations can be compared. This 
approach provides a reference point that is durable for many 
hybridizations (24). Scanning is performed with the Axon 
GenePix 4000B microarray scanner. The ratio of green signal 
to red signal is calculated after background subtraction and 
normalization using the global Lowess (Locally Weighted 
Scatter plot Smoothing) regression algorithm (MIDAS, 
TIGR Microarray Data Analysis System), which was found 
to produce the best within-slide normalization to minimize 
the intensity-dependent differences between the dyes (http://
www.exiqon.com). The positive effect of this normalization 
is illustrated in 2 different plots for each slide. The Cy3/Cy5 
ratios were calculated as the treated group/untreated group 
signals x log2. The statistical significance of differentially 
expressed microRNA was analyzed by t-test.
Microarray data accession number. The microarray data 
discussed in this study have been deposited in the NCBI's 
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.
gov/geo/) and are accessible through GEO series accession 
number GSE23927 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE23927). All data in this study are MIAME 
compliant.
Quantification of the microRNA expression in prolactinoma 
specimens. Stem-loop real-time RT-PCR (qRT-PCR) was 
used in the analysis of microRNA expression. The primers 
for the analysis of microRNAs expression were designed 
according to Chen et al (25). Mixtures of 1 µg of total RNAs 
together with 50 nM reverse primer, 2 units of the RNAase 
inhibitor (Toyobo, Osaka, Japan), 5 units of M-MLV reverse 
transcriptase (Toyobo) and 0.5 µM dNTP were used for each 
RT reaction. The internal control U6 was reverse transcribed 
in parallel. The reactions were incubated for 30 min at 16˚C, 
30 min at 42˚C, 15 min at 70˚C and then held at 4˚C. The 
qRT-PCR reaction was performed on the Applied Biosystems 
7500 detection system by a 20 µl reaction system (Toyobo) 
including 10 µl SYBR-Green Real-time PCR Master Mix-plus, 
2 µl Plus solution, 2 µl each specific forward and reverse 
primers, 1 µl RT product of total RNA and 3 µl DEPC water. 
The reaction was performed at 95˚C for 2 min, followed by 
40 amplification cycles at 95˚C for 15 sec and 60˚C for 1 min. 
Melting curves were generated for each real-time RT-PCR to 
verify the specificity of each PCR reaction. The Ct (threshold 
cycle) value is defined as the fractional cycle number at which 
the fluorescence passed the fixed threshold. ∆Ct represents the 
expression difference between the target microRNA and the 
normalizer: ∆Ct=Ct(mir)-Ct(normalizer). The ∆∆Ct method 
recommended by the manufacturer was used to compare rela-
tive expression levels between the groups.
Quantification of gene expression in prolactinoma specimens. 
cDNA synthesis was carried out via ReverTra Ace reverse 
transcriptase (Toyobo) with oligo (dT)18 primers. Semi-
quantitative PCR was performed with various forward and 
reverse primers. qRT-PCR was carried out using SYBR-Green 
RT-PCR kit (Toyobo) and was performed on the Applied 
Biosystems 7500 detection system. Each PCR cycle included 
94˚C for 30 sec, 60˚C for 30 sec and 72˚C for 1 min. GAPDH 
was used as the internal control. Similarly, ∆Ct represents the 
expression difference between the target gene and the normal-
izer: ∆Ct=Ct(gene)-Ct(normalizer). The normalized gene 
expression in a sample was expressed with 2-∆∆Ct.
Identification of predicted miRNA targets, gene ontology 
category and pathway analysis. The predicted target mRNAs 
of 4 miRNAs (miR-206, miR-516b, miR-550 and miR-671-5p) 
were performed by search algorithms, TargetScan (http://www.
targetscan.org/). These putative target genes were loaded to 
DAVID Bioinformatics Resources 6.7 (26) where GO analysis 
and KEGG pathway analysis were applied in order to uncover 
the miR-Gene Regulatory Network. In detail, two-side Fisher's 
exact tests were used to classify the GO category and KEGG 
pathway, and the false discovery rate (FDR) was calculated to 
correct the P-value. P-value <0.05 and FDR <0.05 were used 
as a threshold to select significant GO categories and KEGG 
pathways.
Statistical analysis. As the data for miRNA and gene relative 
expression levels did not fit a Gaussian distribution, the expres-
sion levels were characterized by their median and ranges 
from the 25th to the 75th percentile, rather than their mean and 
coefficient of variation. A non-parametric test (Mann-Whitney 
U test) was used to evaluate the difference of microRNA 
and relative gene expression between treated and untreated 
prolactinomas with bromocriptine. P<0.05 was considered 
to indicate a significant difference. Correlation between the 
expression of microRNAs and target genes in human pituitary 
adenomas was confirmed using the Spearman's correlation 
coefficient analyses. All calculations were performed with the 
software SPSS 13.0.
Results
microRNAs differentially expressed in treated and untreated 
prolactinomas with bromocriptine by microarray. In order to 
reduce the false negative rate, we considered a 1.2-fold-change 
and P-value of 0.1 as the necessary indicators according to this 
microarray data. The initial analysis of microRNA expression 
data generated a list of 71 microRNAs with a 1.2-fold lower 
expression in treated prolactinomas compared with untreated 
tumors, of which 6 microRNAs were downregulated in treated 
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prolactinomas with a P-value <0.1. Inversely, the data also 
generated a list of 80 microRNAs, with 1.2-fold or higher 
expression in treated prolactinomas compared with untreated 
tumors, of which 9 microRNAs were upregulated in treated 
prolactinomas with a P-value <0.1 (Table II; Fig. 1A). Among 
these 15 microRNAs, 4 microRNAs were found to be signifi-
cantly differentially expressed with a P-value <0.05 between 
the 2 groups by microarray; 3 of these were upregulated and 
the other was downregulated (Table II; Fig. 1B).
Validation of differentially expressed microRNAs by semi-
quantitative RT-PCR. In order to further validate microarray 
results, we performed qRT-PCR expression analysis for the 
15 differentially expressed microRNAs whose P-value was 
<0.1 by microarray (Table III). The expression analysis of 
these selected microRNAs was carried out on specimens 
from the 15 patients (Table I). Melting curves were generated 
for each real-time RT-PCR to verify the specificity of each 
PCR reaction. All the 15 mature microRNAs were expressed 
in 15 prolactinoma samples. Expression of microRNAs was 
normalized with respect to U6 gene expression and by using 
the relative quantification approach previously described 
(27). Relative expression of 3 specific microRNAs, miR-206, 
miR-516b and miR-550 were significantly higher in the 
treated prolactinomas compared to untreated prolactinomas 
(P=0.029, P=0.006 and P=0.024 respectively) (Table III and 
Table II. microRNAs differentially expressed in treated and untreated prolactinomas with bromocriptine by microarray.
 Mean ± SD
 ----------------------------------------------------------------------------------------------
miRNA Group A (treated) Group B (untreated) Group A/Group B P-value
miR-206 1.192±0.058 0.938±0.046 1.26 0.014
miR-516b 1.191±0.066 0.923±0.137 1.28 0.080
miR-630 1.186±0.049 0.966±0.104 1.22 0.076
miR-617 1.184±0.081 0.979±0.078 1.20 0.096
miR-576-3p 1.263±0.164 0.833±0.154 1.51 0.075
miR-374b 1.136±0.047 0.913±0.083 1.24 0.053
miR-516a-5p 1.200±0.066 0.955±0.110 1.25 0.075
miR-488 1.216±0.168 0.867±0.096 1.40 0.092
miR-550 1.212±0.060 0.905±0.169 1.34 0.096
miR-491-5p 0.833±0.096 1.342±0.096 0.62 0.064
miR-487b 0.697±0.131 1.389±0.055 0.50 0.040
miR-S1-5p 0.855±0.107 1.472±0.336 0.58 0.082
miR-585 0.797±0.160 1.227±0.134 0.64 0.064
miR-671-5p 0.608±0.153 1.081±0.112 0.56 0.031
miR-377 0.866±0.048 1.100±0.032 0.78 0.006
Figure 1. Heat Map shows an unsupervised hierarchical clustering result of microRNAs. In the Cy3/Cy5 ratio image, red denotes a higher expression level than 
in the common reference; green, lower expression level than the common reference. In the lower table, each line represents a miRNA, and each row represents 
a sample (slide). (A) Fifteen microRNAs differentially expressed between the treated and untreated prolactinomas with a P-value <0.1. (B) Nine microRNAs 
differently expressed between the treated and untreated prolactinomas with a P-value <0.05.
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Fig. 2A-C). For another microRNA, miR-671-5p, the relative 
expression was significantly lower in treated prolactinomas 
(P=0.042) (Fig. 2D).
Gene ontology (GO) category and pathway analysis. Total 
putative target genes (1096) for miR-206, miR-516b, miR-550 
and miR-671-5p were found by TargetScan (data not shown). 
Figure 2. Four microRNAs differentially expressed between treated and untreated prolactinomas by RT-PCR. (A) Boxplots showing significantly higher 
expression of (A) miR-206 (P=0.029); (B) miR-516b (P=0.006) and (C) miR-550 (P=0.024); boxplot showing significantly lower expression of (D) miR-671-5p 
(P=0.042).
Table III. microRNAs differentially expressed in treated and untreated prolactinomas with bromocriptine by RT-PCR.
miRNAs Group A (treated) median (p25, p75) Group B (untreated) median (p25, p75) P-value
miR-206 0.75 (0.70, 0.90) 0.55 (0.48, 0.69) 0.029
miR-516b 1.61 (1.10, 1.82) 0.30 (0.94, 0.61) 0.006
miR-630 1.00 (0.43, 369.09) 0.28 (0.75, 1.18) 0.165
miR-617 1.44 (0.91, 26.05) 0.77 (0.24, 1.41) 0.171
miR-576-3p 0.51 (0.24, 12.61) 0.25 (0.23, 0.42) 0.165
miR-374b 0.75 (0.16, 0.93) 0.59 (0.39, 0.87) 0.953
miR-516a-5p 4.93 (0.67, 8.95) 0.94 (0.50, 3.37) 0.310
miR-488 0.19 (0.05, 0.74) 0.25 (0.06, 1.02) 0.859
miR-550 0.75 (0.30, 0.34) 0.45 (0.14, 0.52) 0.024
miR-491-5p 0.05 (0.01, 0.77) 0.46 (0.21, 1.60) 0.635
miR-487b 0.62 (0.33, 1.20) 0.47 (0.32, 1.62) 0.833
miR-s1-5p 0.95 (0.31, 7.12) 0.45 (0.21, 1.60) 0.635
miR-585 2.65 (0.69, 5.42) 0.98 (0.23, 3.65) 0.374
miR-671-5p 1.24 (0.87, 1.85) 2.66 (1.62, 2.92) 0.042
miR-377 0.79 (0.62, 1.35) 0.65 (0.40, 1.09) 0.310
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Figure 3. (A) GO category for putative target genes. P-value <0.05 and FDR <0.05 were used as a threshold to select significant GO categories. (B) KEGG 
pathway analysis for putative target genes. P-value <0.05 and FDR <0.05 were used as a threshold to select significant KEGG pathways; lgP is the negative 
logarithm of the P-value.
Figure 4. microRNA-gene-network. Yellow box nodes represent microRNA, and red cycle nodes represent mRNA. Edges describe the inhibitory effects of 
microRNA on mRNA.
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These genes were classified into different functional catego-
ries according to Gene Ontology (GO) project for biological 
processes, molecular function and cellular component. The 
main GO categories for these genes were protein binding, 
binding, intracellular, positive regulation of cellular process, 
regulation of primary metabolic process and cell part (Fig. 3A). 
The KEGG pathway analysis for these putative target genes 
showed that the genes were involved in adherens junction, 
axon guidance, mTOR signaling pathway, pathways in cancer, 
neurotrophin signaling pathway, TGF-β signaling pathway, 
MAPK signaling pathway (Fig. 3B). Genes involved in these 
enriched KEGG pathways and in the related GO category 
were selected. Additionally, miRNA-mRNA network analysis 
integrated these miRNAs and their putative target genes by 
outlining the interactions of miRNA and these selected genes 
(Fig. 4).
Expression of related genes of microRNAs. The role of differ-
entially expressed microRNAs in the pharmacotherapeutic 
mechanism of prolactinoma. Four genes that played an impor-
tant role in the TGF-β and the MAPK signaling pathway, 
platelet-derived growth factor α polypeptide (PDGFA), bone 
morphogenetic protein 4 (BMP4), platelet-derived growth 
factor receptor α polypeptide (PDGFRA) and bone morpho-
genetic protein receptor type II (BMPR2), were selected to 
assess differential expression in the treated prolactinoma vs. 
untreated prolactinoma using the qRT-PCR assay according 
to the miRNA-mRNA network (Fig. 4). As shown in Fig. 5, 
PDGFA was significantly upregulated in treated prolactinomas 
compared with untreated prolactinomas (P=0.006) (Fig. 5A); 
while BMP4 was significantly downregulated in treated 
prolactinomas (P=0.048) (Fig. 5B). However, expression of 2 
other genes, PDGFRA and BMPR2, did not show significant 
difference between the 2 groups (Table IV). A positive correla-
tion was further found between PDGFA and 2 microRNAs, 
miR-516b and miR-550 (r=0.769, P=0.003; r=0.785, P=0.011, 
respectively).
Discussion
To the best of our knowledge, this is the first study to iden-
tify the microRNAs associated with prolactinomas treated 
with bromocriptine. In the present study, we confirmed that 
miR-206, miR-671-5p, miR-516b and miR-550 were signifi-
cantly differentially expressed in treated prolactinomas versus 
untreated prolactinomas by qRT-PCR. Similarly, Bottoni 
et al found 6 microRNAs differentially expressed in treated 
NFPA vs. non-treated non-functioning pituitary adenoma 
(NFPA): 3 microRNAs (miR-134, miR-155 and miR-148) were 
upregulated and 3 (miR-29b, miR-29c and miR-200a) were 
downregulated (15). However, we did not observe the differ-
ential expression of mir-200a between pharmacologically 
Figure 5. Two genes differentially expressed between treated and untreated prolactinomas. (A) Boxplot showing significantly different expression of PDGFA 
(P=0.006). (B) Boxplot showing significant different expression of BMP4 (P=0.048).
Table IV. Genes differentially expressed in treated and untreated prolactinomas with bromocriptine by RT-PCR.
Genes Group A (treated) median (p25, p75) Group B (untreated) median (p25, p75) P-value
PDGFA 0.36 (0.20, 0.86) 0.05 (0.04, 0.07) 0.006a
PDGFRA 1.61 (1.15, 3.33) 1.68 (0.08, 4.05) 0.839
BMP4 1.04 (1.00, 8.68) 136.56 (7.31, 231.05) 0.048
BMPR2 1.38 (0.54, 4.47) 0.49 (0.35, 2.75) 0.536
aPositive correlation between PDGFA and miR-516b (r=0.769, P=0.003); PDGFA and miR-550 (r=0.785, P=0.011) was identified using 
Spearman's correlation coefficient analysis.
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treated and non-treated prolactinomas and the others were not 
detected by microRNA microarray.
In our study, we found that miR-206 was upregulated in 
treated prolactinomas. The antitumoral action of bromocrip-
tine is connected with the induction of apoptosis (28). miR-206 
identified as a pro-apoptotic activator, blocks the antiapoptotic 
activity of Notch3 (29). miR-206 has also been demonstrated 
to act as a potent tumor suppressor in c-Met-overexpressing 
tumors (30). Furthermore, miR-206 expression associated 
with genes linked to MAP kinase pathway activation (31). 
With regard to miR-516, previous studies have indicated that 
miR-206 may not only act as a tumor suppressor microRNA, 
but also that it downregulates metastasis-related target genes 
by associated DNA methylation (32) and is connected with 
the induction of apoptosis (28). In our study, miR-516b and 
miR-550 were significantly upregulated in treated prolacti-
nomas, suggesting that these microRNAs may have a role in 
promoting prolactin-induced cell apoptosis. As to miR-671, it 
may regulate gene expression to promote tumor growth (33). 
In our series, miR-671-5p was significantly downregulated in 
treated prolactinomas in agreement with a previous report (33).
In order to gain insight into the function of these miRNAs, 
GO term and KEGG pathway annotation were applied to their 
target genes. GO enrichment and KEGG pathway analysis 
organized genes targeted by these 4 miRNAs into hierarchical 
categories based on biological processes, and then outlined the 
effects of miRNAs on pharmacotherapy mechanism of prolac-
tinomas. As a result, KEGG annotation showed that important 
proliferative (MAPK, Wnt, VEGF and cell cycle), survival 
(mTOR and TGF-β), adhesive (adherens junction, tight junc-
tion, focal adhension and gap junction), signaling pathways 
were abundant among the significantly enriched pathways. The 
MAPK and TGF-β signaling pathway have been reported to 
be involved in the subsequent pharmacotherapeutic effects of 
prolactinoma through inhibiting lactotroph cell proliferation 
and inducing apoptosis through D2 receptors (3-5). Initially, 
prolactinomas were treated by bromocriptine activating the 
D2 receptor which is a G protein-coupled receptor protein. 
Consistently, GO annotation showed that protein binding had 
the highest enrichment score.
The miRNA-mRNA interaction network analysis further 
integrated the bioinformatic findings, and displayed some 
critical genes of the related signaling pathway. PDGFA/
PDGFRA involved in the MAPK signaling pathway and 
BMP4/BMPR2 involved in TGF-β signaling pathway were 
selected for further examination at the mRNA level. Data from 
our study shows that expression of PDGFA was significantly 
upregulated in treated prolactinomas. PDGFA can act directly 
on pituitary cells to selectively decrease the production of PRL 
(34). Meanwhile, PDGFA is shown to increase downstream of 
p44/42 MAPK phosphorylation in a dose-dependent manner 
(35), which results in the inhibition of cell cycle inhibitors (36). 
In addition, a positive correlation was found between PDGFA 
and 2 microRNAs, miR-516b and miR-550. An intermediate 
or secondary microRNA-driven regulatory mechanism, such 
as a transcription factor (37) may exist between miR-516b, 
miR-550 and PDGFA instead of a direct interaction.
Expression of BMP4 was significantly downregulated 
in treated prolactinomas in this study. BMP4 plays a key 
role not only in the initial development of the anterior 
pituitary (38) but also in the pathogenesis of differentiated 
pituitary adenoma (39). A prior study has demonstrated that 
bromocriptine suppresses BMP4 signaling in GH3 cells 
(40), and downregulation of BMP4 may suppress prolactin 
cell proliferation (39). Moreover, BMP4 is considered a 
predicted putative target gene of miR-206 by computational 
search algorithms. Therefore, the fact that overexpression 
of miR-206 in the treated prolactinomas was accompanied 
by downregulation of BMP4 indicates the possibility that 
miR-206 may inhibit tumor proliferation and induce apoptosis 
through the TGF-β signaling pathway in bromocriptine-
treated prolactinomas.
In conclusion, we identified 4 miRNAs, which may be 
involved in the pharmacotherapy mechanism of prolactinoma. 
Their actions may regulate multiple functions, especially 
protein binding. These 4 miRNAs may be involved in several 
signaling pathways. PDGFA and BMP4 may act as critical regu-
lators in the MAPK and TGF-β signaling pathway respectively. 
However, the detailed function associated with these miRNAs 
in prolactinoma pharmacotherapy needs further investigation 
and the target genes of miRNAs need further experimental 
validation.
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